AIMS/HYPOTHESIS: The chemokines monocyte chemoattractant protein-1 (MCP-1), IL-8 and interferon-gamma-inducible protein-10 (IP-10) are released by adipocytes and appear to be involved in atherosclerosis. We hypothesised that these chemokines may be risk factors for the development of type 2 diabetes. SUBJECTS AND METHODS: Using a case-cohort design based on data from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/Kooperative Gesundheitsforschung in der Region Augsburg/Cooperative Health Research in the Region of Augsburg (KORA Augsburg) study, chemokine levels at baseline were analysed in 526 individuals with and 1,695 individuals without incident type 2 diabetes. The mean follow-up time was 10.8 years. RESULTS: MCP-1 was associated with type 2 diabetes, largely independently of classic risk factors, whereas various clinical and metabolic parameters as well as lifestyle factors were major confounders of the association of IL-8 and IP-10 with type 2 diabetes. Further adjustment for C-reactive protein (CRP) and IL-6 had no impact on the observed associations. The hazard ratio (HR) for subjects with systemic concentrations of all three chemokines (MCP-1, IL-8 and IP-10) above the respective median compared with those with all chemokines below or equal to the median was 1.79 (95% CI 1.18-2.72) and was comparable with the HR for elevated CRP and IL-6 together (adjusted for age, sex, survey, BMI, systolic blood pressure, total cholesterol:HDL cholesterol ratio, physical activity, alcohol intake, smoking and parental history of diabetes). CONCLUSIONS/ INTERPRETATION: Elevated concentrations of MCP-1, IL-8 and IP-10 are associated with incident type 2 diabetes. Whereas the association of IL-8 and IP-10 with diabetes was attenuated by multivariable adjustment, high MCP-1 levels contributed to diabetes risk independently of previously described clinical, metabolic and immunological risk factors.
AIMS/HYPOTHESIS: The chemokines monocyte chemoattractant protein-1 (MCP-1), IL-8 and interferon-gamma-inducible protein-10 (IP-10) are released by adipocytes and appear to be involved in atherosclerosis. We hypothesised that these chemokines may be risk factors for the development of type 2 diabetes. SUBJECTS AND METHODS: Using a case-cohort design based on data from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/Kooperative Gesundheitsforschung in der Region Augsburg/Cooperative Health Research in the Region of Augsburg (KORA Augsburg) study, chemokine levels at baseline were analysed in 526 individuals with and 1,695 individuals without incident type 2 diabetes. The mean follow-up time was 10.8 years. RESULTS:MCP-1 was associated with type 2 diabetes, largely independently of classic risk factors, whereas various clinical and metabolic parameters as well as lifestyle factors were major confounders of the association of IL-8 and IP-10 with type 2 diabetes. Further adjustment for C-reactive protein (CRP) and IL-6 had no impact on the observed associations. The hazard ratio (HR) for subjects with systemic concentrations of all three chemokines (MCP-1, IL-8 and IP-10) above the respective median compared with those with all chemokines below or equal to the median was 1.79 (95% CI 1.18-2.72) and was comparable with the HR for elevated CRP and IL-6 together (adjusted for age, sex, survey, BMI, systolic blood pressure, total cholesterol:HDL cholesterol ratio, physical activity, alcohol intake, smoking and parental history of diabetes). CONCLUSIONS/ INTERPRETATION: Elevated concentrations of MCP-1, IL-8 and IP-10 are associated with incident type 2 diabetes. Whereas the association of IL-8 and IP-10 with diabetes was attenuated by multivariable adjustment, high MCP-1 levels contributed to diabetes risk independently of previously described clinical, metabolic and immunological risk factors.
Authors: Katherine Esposito; Francesco Nappo; Francesco Giugliano; Carmen Di Palo; Myriam Ciotola; Michelangela Barbieri; Giuseppe Paolisso; Dario Giugliano Journal: Diabetes Care Date: 2003-05 Impact factor: 19.112
Authors: Natalie Khuseyinova; Armin Imhof; Gerlinde Trischler; Dietrich Rothenbacher; Winston L Hutchinson; Mark B Pepys; Wolfgang Koenig Journal: Clin Chem Date: 2003-10 Impact factor: 8.327
Authors: Rajat Deo; Amit Khera; Darren K McGuire; Sabina A Murphy; Januario de P Meo Neto; David A Morrow; James A de Lemos Journal: J Am Coll Cardiol Date: 2004-11-02 Impact factor: 24.094
Authors: S Müller; S Martin; W Koenig; P Hanifi-Moghaddam; W Rathmann; B Haastert; G Giani; T Illig; B Thorand; H Kolb Journal: Diabetologia Date: 2002-05-08 Impact factor: 10.122
Authors: E Simeoni; M M Hoffmann; B R Winkelmann; J Ruiz; S Fleury; B O Boehm; W März; G Vassalli Journal: Diabetologia Date: 2004-09-02 Impact factor: 10.122
Authors: Susan J Burke; Danhong Lu; Tim E Sparer; Thomas Masi; Matthew R Goff; Michael D Karlstad; J Jason Collier Journal: Am J Physiol Endocrinol Metab Date: 2013-11-26 Impact factor: 4.310
Authors: C Herder; N Klopp; J Baumert; M Müller; N Khuseyinova; C Meisinger; S Martin; T Illig; W Koenig; B Thorand Journal: Diabetologia Date: 2007-08-22 Impact factor: 10.122
Authors: Christian Herder; Astrid Zierer; Wolfgang Koenig; Michael Roden; Christa Meisinger; Barbara Thorand Journal: Diabetes Care Date: 2009-07-10 Impact factor: 19.112
Authors: Maren Carstensen; Christian Herder; Mika Kivimäki; Markus Jokela; Michael Roden; Martin J Shipley; Daniel R Witte; Eric J Brunner; Adam G Tabák Journal: Diabetes Date: 2010-02-25 Impact factor: 9.461
Authors: C Herder; M Peltonen; W Koenig; K Sütfels; J Lindström; S Martin; P Ilanne-Parikka; J G Eriksson; S Aunola; S Keinänen-Kiukaanniemi; T T Valle; M Uusitupa; H Kolb; J Tuomilehto Journal: Diabetologia Date: 2009-01-08 Impact factor: 10.122
Authors: Christian Herder; Eric J Brunner; Wolfgang Rathmann; Klaus Strassburger; Adam G Tabák; Nanette C Schloot; Daniel R Witte Journal: Diabetes Care Date: 2008-12-10 Impact factor: 19.112